Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Apogee Therapeutics, Inc. - Common Stock
(NQ:
APGE
)
70.92
-1.39 (-1.92%)
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apogee Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
February 03, 2025
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
January 29, 2025
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
December 10, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
December 02, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Announces Agenda for Virtual R&D Day
November 29, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
↗
November 25, 2024
Via
Benzinga
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
November 18, 2024
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
November 12, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
November 04, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
October 24, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
October 16, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
September 12, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
September 09, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
August 19, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
APGE Stock Earnings: Apogee Therapeutics Meets EPS for Q2 2024
↗
August 12, 2024
APGE stock results show that Apogee Therapeutics met analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
August 12, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
July 18, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
↗
July 14, 2024
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...
Via
Benzinga
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
↗
July 11, 2024
Via
Benzinga
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
May 28, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
May 23, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
May 15, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024
↗
May 13, 2024
APGE stock results show that Apogee Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
May 13, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Earnings Superstars: 3 Stocks Primed to Outperform This Quarter
↗
May 08, 2024
Discover how Nvidia, Apogee Therapeutics and JD.com stand out as earnings outperformers in their respective sectors.
Via
InvestorPlace
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
May 06, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
March 25, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
↗
March 14, 2024
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
March 12, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
March 07, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
